C4 Therapeutics (CCCC) Accumulated Depreciation & Amortization (2019 - 2026)

C4 Therapeutics has reported Accumulated Depreciation & Amortization for 8 years, with the latest figure at $404000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation & Amortization fell 11.4% year-over-year to $404000.0; the trailing twelve-month figure through Mar 2026 stood at $404000.0 (down 11.4% YoY), and the FY2025 full-year result was $10.8 million, up 16.68% from the prior year.
• Accumulated Depreciation & Amortization for Q1 2026 stood at $404000.0, down from $10.8 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $10.8 million in Q4 2025, with the low at $404000.0 in Q1 2026.
• Average Accumulated Depreciation & Amortization over 5 years is $4.4 million, with a median of $1.5 million recorded in 2025.
• Year-over-year, Accumulated Depreciation & Amortization increased 19.78% in 2023 and slumped 94.78% in 2024.
• Tracing CCCC's Accumulated Depreciation & Amortization over 5 years: stood at $8.1 million in 2022, then declined by 4.43% to $7.8 million in 2023, then advanced by 18.97% to $9.2 million in 2024, then grew by 16.68% to $10.8 million in 2025, then sank by 96.25% to $404000.0 in 2026.
• The last three Accumulated Depreciation & Amortization figures came in at $404000.0 (Q1 2026), $10.8 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.

Peer Comparison